刘英，男，博士，讲师，硕士研究生导师。
一、个人简介
2015年毕业于大连理工大学生命科学与技术学院，获得工学博士学位，同年进入青岛大学转化医学研究院工作。2020年入选青岛大学青年卓越人才工程。现为山东省医学伦理学会理事、山东中西医结合学会细胞行为组学专业委员会委员。担任Trends in Genetics、EBioMedicine、BBA Reviews on Cancer、Cancer Letters、Heliyon、Frontiers in Oncology、Oncology Research等多个国际高水平SCI学术期刊客座主编、编委和特邀审稿专家。课题组围绕肿瘤和心血管等重大疾病的病理机制开展基础和临床研究，为相关疾病的防治提供新靶点和新策略。迄今为止，已在生物医学相关领域发表SCI论文50余篇，累计被引用次数2100余次，H指数27。其中以第一作者/通讯作者在Molecular Cancer、EBioMedicine、Cancer Letters等国际权威期刊上发表SCI论文31篇（1篇IF³25，3篇IF³9，9篇IF³5），累计影响因子162，单篇最高被引297次，ESI前1%高被引论文6篇，杂志封面论文3篇。授权国家实用新型专利1项。作为项目负责人主持国家自然科学基金、山东省自然科学基金、青岛市博士后应用研究等项目3项。研究成果获辽宁省自然科学学术成果奖一等奖1项、辽宁省自然科学学术成果奖三等奖1项、大连市科学技术奖励一等奖1项、大连市科学技术奖励二等奖1项、大连市自然科学优秀学术论文一等奖1项。带领团队获得山东省大学生创新创业训练计划项目2项、青岛大学大学生创新创业训练计划项目3项、青岛大学“互联网+”大学生创新创业大赛优秀奖1项。作为主讲教师，承担10门本科生课程的教学工作，其中3门入选青岛大学优质课程。
二、主要研究方向
1、非编码RNA作用机制
2、核受体信号转导
3、蛋白质翻译后修饰
4、生物标志物鉴定
三、代表性科研成果（#第一作者，*通讯作者）
1. Xiaoge Li#, Chunying Shi#, Runxue Zhou, Xinhui Chen, Qingling Xu, Chunyige Zhao, Mengyao Ma, Xiang Ao*, Ying Liu* (2024). Modified EBP-bFGF targeting endogenous renal extracellular matrix protects against renal ischemia-reperfusion injury in rats. Journal of Biomedical Materials Research: Part A, doi: 10.1002/jbm.a.37730. (IF: 3.9)
2. Ying Liu#, Wei Ding, Jianxun Wang, Xiang Ao*, and Junqiang Xue* (2023). Non-coding RNA-mediated modulation of ferroptosis in cardiovascular diseases. Biomedicine & Pharmacotherapy, 164:114993. (IF: 6.9)
3. Xiang Ao#, Wei Ding, Xiaoge Li, Qingling Xu, Xinhui Chen, Xuehao Zhou, Jianxun Wang, and Ying Liu * (2023). Non-coding RNAs regulating mitochondrial function in cardiovascular diseases. Journal of Molecular Medicine, 101(5):501-526. (IF: 4.8)
4. Ying Liu#, Wei Ding, Jianxun Wang, Xiang Ao*, and Junqiang Xue* (2023). Non-coding RNAs in lung cancer: Molecular mechanisms and clinical applications. Frontiers in Oncology, 13:1256537. (IF: 3.5)
5. Ying Liu#,*, Yu Wang, Xiaoge Li, Yi Jia, Jianxun Wang, and Xiang Ao (2022). FOXO3a in cancer drug resistance. Cancer Letters, 540:215724. (IF: 9.1)
6. Ying Liu#,*, Xiang Ao, Wanpeng Yu, Yuan Zhang, and Jianxun Wang (2022). Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer. Molecular Therapy Nucleic Acid, 27:50-72. (IF: 6.5)
7. Ying Liu#,*, Xiaoge Li, Xuehao Zhou, Jianxun Wang, and Xiang Ao (2022). FADD as a key molecular player in cancer progression. Molecular Medicine, 28(1):132. (IF: 6)
8. Xiang Ao# and Ying Liu* (2022). Novel insights into circular RNA regulation in arsenic-exposureinduced lung cancer. Molecular Therapy Oncolytics. 27:200-202. (IF: 5.3)
9. Wei Ding#, Ying Liu#, Zhe Su, Qi Li, Jianxun Wang*, and Yufang Gao* (2022). Emerging role of non-coding RNAs in aortic dissection. Biomolecules, 12:1336. (IF: 4.8)
10. Ying Liu#,*, Xiang Ao, Xuehao Zhou, Chengcheng Du, and Shouxiang Kuang (2022). The regulation of PBXs and their emerging role in cancer. Journal of Cellular and Molecular Medicine, 26(5):1363–1379. (IF: 4.3)
11. Ying Liu#,*, Yiwen Li, Chengcheng Du, Shouxiang Kuang, Xuehao Zhou, Jinyu Zhang, and Xiang Ao (2022). Underlying mechanisms of epithelial splicing regulatory proteins in cancer progression. Journal of Molecular Medicine, 100(11):1539-1556. (IF: 4.8)
12. Ying Liu#,*, Xiang Ao, Yi Jia, Xiaoge Li, Yu Wang, and Jianxun Wang (2022). The FOXO family of transcription factors: key molecular playersin gastric cancer. Journal of Molecular Medicine, 100(7):997-1015. (IF: 4.8)
13. Ying Liu#,*, Xiang Ao, Yu Wang, Xiaoge Li, and Jianxun Wang (2022). Long non-coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance. Frontiers in Oncology, 12:841411. (IF: 3.5)
14. Xuehao Zhou, Xiang Ao, Zhaojun Jia, Yiwen Li, Shouxiang Kuang, Chengcheng Du, Jinyu Zhang, and Ying Liu* (2022). Non-Coding RNA in Cancer Drug Resistance: Underlying Mechanisms and Clinical Applications. Frontiers in Oncology, 12:951864. (IF: 3.5)
15. Ying Liu#, Wei Ding, Wanpeng Yu, Yuan Zhang, Xiang Ao*, and Jianxun Wang* (2021). Long non-coding RNAs: Biogenesis, functions, and clinical significance in gastric cancer. Molecular Therapy Oncolytics. 23:458-476. (IF: 5.3)
16. Wenwen Marin#,*, Dennis Marin, Xiang Ao, and Ying Liu* (2021). Mitochondria as a therapeutic target for cardiac ischemia reperfusion injury (Review). International Journal of Molecular Medicine. 47(2):485-499. (IF: 5.7)
17. Ying Liu#,*, Xiang Ao, Guoqiang Ji, Yuan Zhang, Wanpeng Yu, and Jianxun Wang (2021). Mechanisms of action and clinical implications of microRNAs in the drug resistance of gastric cancer. Frontiers in Oncology. 11:768918. (IF: 3.5)
18. Xinyu Liu#, Ying Liu#, Qianshan Wang, Siqi Song, Lingjun Feng*, and Chunying Shi* (2021). The alterations and potential roles of MCMs in breast cancer. Journal of Oncology. 2021:7928937. (IF: 4.5)
19. Xinyu Liu#, Qianshan Wang, Siqi Song, Manman Feng, Xiaoya Wang, Ling Li, Ying Liu*, and Chunying Shi* (2021). Epithelial splicing regulatory protein 1 is overexpressed in breast cancer and predicts poor prognosis for breast cancer patients. Medical Science Monitor. 27:e931102. (IF: 2.2)
20. Xiang Ao#, Wei Ding, Yuan Zhang, Dan Ding, and Ying Liu* (2020).TCF21: a critical transcription factor in health and cancer. Journal of Molecular Medicine, 98(8):1055-1068. (IF: 4.8)
21. Xiang Ao#, Wei Ding, Hu Ge, Yuan Zhang, Dan Ding, and Ying Liu* (2020). PBX1 is a valuable prognostic biomarker for patients with breast cancer. Experimental and Therapeutic Medicine, 20(1):385-394. (IF: 2.4)
22. Haotian Lu#, Chunying Shi#, Xinyu Liu, Chen Liang, Chaochao Yang, Xueqi Wan, Ling Li*, and Ying Liu* (2020). Identification of ZG16B as a prognostic biomarker in breast cancer. Open Medicine, 16(1):1-13. (IF: 1.7)
23. Baowei Li#, Xiong Wang#, Xiaodan Hao, Yanran Liu, Yin Wang, Chan Shan, Xiang Ao, Ying Liu*, Hongchu Bao*, and Peifeng Li* (2020). A novel c.2179T>C mutation blocked the intracellular transport of PHEX protein and caused X-linked hypophosphatemic rickets in a Chinese family. Molecular Genetics & Genomic Medicine, 8(8):e1262. (IF: 1.7)
24. Ying Liu#, Wei Ding, Hu Ge, Murugavel Ponnusamy, Qiong Wang, Xiaodan Hao, Wei Wu, Yuan Zhang, Wanpeng Yu, Xiang Ao*, and Jianxun Wang* (2019). FOXK Transcription Factors: Regulation and Critical Role in Cancer. Cancer Letters, 458:1-12. (IF: 9.1)
25. Ying Liu#,* (2019). Targeting the Non-Canonical AKT-FOXO3a Axis: A Potential Therapeutic Strategy for Oral Squamous Cell Carcinoma. EBioMedicine, 49:6-8. (IF: 9.7)
26. Ying Liu#, Xiang Ao#, Wei Ding, Murugavel Ponnusamy, Wei Wu, Xiaodan Hao, Wanpeng Yu, Yifei Wang, Peifeng Li*, and Jianxun Wang* (2018). Critical role of FOXO3a in carcinogenesis. Molecular Cancer, 17(1):104. (IF: 27.7)
27. Ying Liu#, Xiang Ao, Qiong Wang, Jianxun Wang, Hu Ge* (2018). PiViewer: An open‐source tool for automated detection and display of π–π interactions. Chemical Biology & Drug Design, 92(4), 1809-1814. (IF: 3.2)
28. Chao Qu#, Jia Sun#, Ying Liu#, Xiaobo Wang, Lifen Wang, Chao Han, Qian Chen, Tianhui Guan, Hongyan Li, Yejun Zhang, Yang Wang, Jia Liu, Wei Zou*, and Jing Liu* (2018). Caveolin-1 Facilitated KCNA5 Expression, Promoting Breast Cancer Viability. Oncology Letters,16(4):4829-4838. (IF: 2.5)
29. Ying Liu#, Xiang Ao#, Zhaojun Jia, Xiaoyan Bai, Zhaowei Xu, Gaolei Hu, Xiao Jiang, Min Chen, and Huijian Wu* (2015). FOXK2 Transcription Factor Suppresses ERα-positive Breast Cancer Cell Growth Through Down-Regulating the Stability of ERα via mechanism involving BRCA1/BARD1. Scientific Reports, 5:8796. (IF: 3.8)
30. Xiang Ao#, Ying Liu#, Xiaoyan Bai, Xinjian Qu, Zhaowei Xu, Gaolei Hu, Min Chen, and Huijian Wu* (2015). Association between EHBP1 rs721048(A＞G) polymorphism and Prostate Cancer Susceptibility: A Meta-Analysis of 17 Studies Involving 150,678 Subjects. OncoTargets and Therapy, 8:1671-80. (IF: 2.7)
31. Ying Liu#, Dongdong Chen, Yongheng Xing, Nan Ge, Yuan Zhang, Jing Liu, Wei Zou* (2014). A new oxovanadium complex enhances renal function by improving insulin signaling pathway in diabetic mice. Journal of Diabetes and Its Complications, 28(3):265-72. (IF: 2.9)
四、授权专利
1、一种免疫细胞采集储存设备（发明专利，专利号：ZL202321336387.9）。
五、主持的科研项目
1、国家自然科学基金青年基金项目、81702785、SUMO化修饰对FOXK2的调控及其在乳腺癌发生发展中的分子机制研究、2017/1-2020/12、20万元，主持。
2、山东省自然科学基金培养基金项目、ZR2017PH013、FOXK2蛋白的SUMO化修饰对ERα阳性乳腺癌细胞增殖的影响及机制研究、2017/07-2018/12、4万元，主持。
3、青岛市博士后应用研究项目、2016067、FOXK2的SUMO化修饰对乳腺癌细胞增殖的调控机理、2016/11-2018/06、5万元，主持。
六、科研奖励
1、辽宁省自然科学学术成果奖一等奖1项（第1位，证书编号：161803701433921）
2、辽宁省自然科学学术成果奖三等奖1项（第2位，证书编号：161803701433911）
3、大连市自然科学优秀学术论文一等奖1项（第1位，证书编号：2015-023）
4、大连市科学技术奖励一等奖1项（第7位，证书编号：2012J-1-09-10）
5、大连市科学技术奖励二等奖1项（第6位，证书编号：2016J-2-24-R07）
七、主要荣誉称号
1、2023年度青岛大学转化医学研究院党支部优秀党员
2、2022年度青岛大学转化医学研究院党支部优秀党员
3、2022年青岛大学大学生志愿者寒暑假社会实践优秀指导教师
4、2021年度青岛大学转化医学研究院党支部优秀党员
5、2020年度青岛大学转化医学研究院党支部优秀党员
6、2019年度青岛大学转化医学研究院党支部优秀党员
7、2018年度青岛大学转化医学研究院党支部优秀党员
八、学术任职情况
1、Heliyon（SCIE），顾问委员会委员（Advisory Board Member）
2、Oncology Research（SCIE），编辑委员会会委员（Editorial Board Member）
3、Frontiers in Oncology（SCIE），执行编辑（Handling Editor）
4、Oncology Letters（SCIE），客座主编（Guest Editor）、编辑委员会会委员（Editorial Board Member）
5、山东省医学伦理学会理事
6、山东中西医结合学会细胞行为组学专业委员会委员
7、中国生物化学与分子生物学学会会员
8、中国细胞生物学学会会员
师资队伍
